	2021																				
	F	Feb	Ma		Mar			Apr		May		Jun			Jul				Aug		
BNT162b2																					
Market approval																					
Approval for individuals aged ≥16 years		Feb	14	1																	
Approval for individuals aged 12–15 years													May	y 31							
Vaccination program with public funding																					
Healthcare professionals		Fe	b 1	17																	
Older adults aged ≥65 years								Δ	pr 1:	2											
Indivisuals aged 12–64 years													Jui	n 1*							
mRNA-1273																					
Market approval																					
Approval for individuals aged ≥18 years												М	ay 2	1							
Approval for individuals aged 12–17 years																			Jul 2	26	
Vaccination program with public funding																					
Older adults aged ≥65 years													May	24							
Individuals aged 18–64 years															Jun	17	1				
Individuals aged 12–17 years																			4	ug 2	
AZD1222		•													•						
Market approval																					
Approval for individuals aged ≥18 years												M	ay 2	1							
Vaccination program with public funding																					
Options for individuals aged ≥40 years			T						1						T			Т			

**Supplementary Figure 1**: Timeline of COVID-19 vaccine approval and administration in Japan. \*Vaccination of individuals aged 12 to 64 years prioritized those with underlying medical conditions.

The data source was the National Institute of Infectious Diseases, Japan and the Pharmaceuticals and Medica Devices Agency, Japan.